CN101857595B - Quinnazolidone derivative, preparation method thereof and purpose of serving as anticarcinogen - Google Patents

Quinnazolidone derivative, preparation method thereof and purpose of serving as anticarcinogen Download PDF

Info

Publication number
CN101857595B
CN101857595B CN2010101863715A CN201010186371A CN101857595B CN 101857595 B CN101857595 B CN 101857595B CN 2010101863715 A CN2010101863715 A CN 2010101863715A CN 201010186371 A CN201010186371 A CN 201010186371A CN 101857595 B CN101857595 B CN 101857595B
Authority
CN
China
Prior art keywords
compound
corticosterone
hydroxy
400mhz
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010101863715A
Other languages
Chinese (zh)
Other versions
CN101857595A (en
Inventor
黄志纾
古练权
谭嘉恒
颜金武
候金强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
National Sun Yat Sen University
Original Assignee
National Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Sun Yat Sen University filed Critical National Sun Yat Sen University
Priority to CN2010101863715A priority Critical patent/CN101857595B/en
Publication of CN101857595A publication Critical patent/CN101857595A/en
Application granted granted Critical
Publication of CN101857595B publication Critical patent/CN101857595B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention belongs to the medicine and chemical industry field, which discloses a quinnazolidone derivative, a preparation method thereof and a purpose of serving as anticarcinogen. The structural formula of the quinnazolidone derivative is that: R1 is F, CL, Br or I, R2 is NH (CH2) nNR4, NR4 or NH(CH2)n-Ar, R3 is NHCO (CH2) nNR4 or CONH (CH2) nNR4, and m equals to 1,2 or 3. -Ar represents various aromatic nucleus, including various heteroaromatic compounds; n equals to 1, 2, 3, 4 or 5; R4 represents C1-6alkyl, C3-6 naphthenic base, piperidyl, morpholinyl, piperazine, or quinoxaline and the like or R1 equals to H, R2 equals to R3 equals to NHCO (CH2) nNR4 or R2 equals to H, R1 equals to R3 equals to NHCO (CH2) nNR4, and m equals to 2 or 3. The invention discloses the preparation method of the quinnazolidone derivative and the purpose of serving as the anticarcinogen at the same time. The quinnazolidone derivative has the advantages of strong inhibitory action on the expression of telomere DNA, c-myc and other proto-oncogenes DNA, obvious inhibitory action on various cancer cell strains, little toxicity on normal cells and wide application space on preparing the anticarcinogen.

Description

A kind of Quinzolone derivatives and preparation method thereof and as the purposes of cancer therapy drug
Technical field
The invention belongs to medicine and chemical field, relate to a kind of Quinzolone derivatives and preparation method thereof, with and be used for the purposes of cancer therapy drug in preparation.
Background technology
Cancer is the principal disease that threatens human health and life security, and according to statistics, the whole world annual newly-increased cancer patients reach about 4,000,000 people.The research and development of cancer therapy drug are the focuses that chemist and medicine scholar pay close attention to always.Seek efficient, highly selective, cancer therapy drug that toxic side effect is little is one of important directions of drug development research.Synthesizing cancer therapy drug for target spot designs with DNA, to the special higher structure design synthesized micromolecule suppressor factor of proto-oncogene DNA such as telomeric dna with important physiological meaning and c-myc, is the important method of development new type anticancer medicine particularly.
The quinazolone Alkaloid is big type of one in the vegeto-alkali, is the primary structure unit of traditional Chinese medicine ingredients febrifugin(e).These compositions mainly are present in the Chinese medicines such as Changshan, Leaf of Indigowoad, NSC 290495, couroupitine A etc. have wide biological activity.Research in recent years shows that the compound that contains this class formation has the multi-biological activity, brings into play multiple pharmacological effect such as anticancer, antibiotic, antiviral.Patented claim 200810027004 disclose a kind of pair of fat amido replace Quinzolone derivatives with and as the application of cancer therapy drug, still, the biological development research of quinazolone class at present is still considerably less.
Summary of the invention
The objective of the invention is to deficiency, the Quinzolone derivatives that a kind of toxicity is little, anticancer effect is good is provided to prior art.
Another object of the present invention is to provide the preparation method of this Quinzolone derivatives.
A further object of the invention is to provide the application of this Quinzolone derivatives.
Invention realizes above-mentioned purpose by the following technical programs:
Invention provides a kind of Quinzolone derivatives, and its structural formula is:
Wherein each group can be one of following arbitrary combination:
Combination one:
R 1Be F, Cl, Br or I;
R 2Be NH (CH 2) nNR 4, NR 4Or NH (CH 2) n-Ar;
R 3Be NHCO (CH 2) nNR 4
M=1,2 or 3.
Wherein ,-Ar can be various aromatic rings, comprises various aromatic heterocycles; N=1,2,3,4 or 5; R 4Group can be C 1-6Alkyl, C 3-6Cycloalkyl, piperidyl, morpholinyl, piperazinyl or pyrrole dislike quinoline base etc.
Combination two:
Except R 3Be CONH (CH 2) nNR 4Outside, other as the combination one;
Combination three:
R 1=H, R 2=R 3=NHCO (CH 2) nNR 4; Perhaps R 2=H, R 1=R 3=NHCO (CH 2) nNR 4
M=2 or 3.
Wherein, n=1,2,3,4 or 5, R 4Group can be C 1-6Alkyl, C 3-6Cycloalkyl, piperidyl, morpholinyl, piperazinyl or pyrrole dislike quinoline base etc.
The present invention provides the preparation method of this Quinzolone derivatives simultaneously, representes as follows:
(1) works as R 1=F, Cl, Br or I, m=1, R 2Be NH (CH 2) nNR 4, NR 4Or NH (CH 2) n-Ar, R 3=NHCO (CH 2) nNR 4The time, building-up process is:
The steps include: that 4,5 two substituted 2-benzaminic acid of halogen and pyrrolidone close ring, obtain compound F 17-hydroxy-corticosterone-I1, F-I1 and different substituted amine compound (NH (CH 2) nNR 4, NR 4Or NH (CH 2) n-Ar) substitution reaction takes place, obtain compound F 17-hydroxy-corticosterone-I2, F-I2 again with the substituted phenyl aldehyde condensation of nitro, obtain chemical combination
Thing F-I3 is then through Na 2The S reduction obtains compound F 17-hydroxy-corticosterone-I4.The substituted alkyl acyl chloride of F-I4 and chlorine [Cl (CH 2) nCOCl] carry out after alkylated reaction obtains the alkylation midbody, again with substituted amine compound (NHR 4) effect, obtain title product (the described Quinzolone derivatives of claim 1) through column chromatography or recrystallization.
(2) work as R 1=F, Cl, Br or I, m=2 or 3, R 2Be NH (CH 2) nNR 4, NR 4Or NH (CH 2) n-Ar, R 3=NHCO (CH 2) nNR 4The time, building-up process is:
The steps include: that 4,5 two substituted 2-benzaminic acid of halogen and various lactan close ring, obtain compound F 17-hydroxy-corticosterone-H1, F-H1 elder generation and the substituted phenyl aldehyde condensation of nitro obtain compound F 17-hydroxy-corticosterone-H2, then through Na 2S reduction obtains compound F 17-hydroxy-corticosterone-H3, F-H3 again with different substituted amine compound (NH (CH 2) nNR 4, NR 4Or NH (CH 2) n-Ar) substitution reaction takes place, obtain compound F 17-hydroxy-corticosterone-H4, the substituted alkyl acyl chloride of F-H4 and chlorine [Cl (CH 2) nCOCl] carry out after alkylated reaction obtains the alkylation midbody, again with substituted amine compound (NHR 4) effect, obtain title product (the described Quinzolone derivatives of claim 1) through column chromatography or recrystallization.
(3) work as R 1=F, Cl, Br or I, m=1, R 2Be NH (CH 2) nNR 4, NR 4Or NH (CH 2) n-Ar, R 3=CONH (CH 2) nNR 4The time, building-up process is:
The steps include: by before said process, obtain F-I2 after, with the condensation of 4-carbamoyl benzoate, obtain compound F 17-hydroxy-corticosterone-C3, F-C3 again with different substituted amine compound (NH (CH 2) nNR 4) reaction, obtain title product (the described Quinzolone derivatives of claim 2) through column chromatography or recrystallization.
(4) work as R 1=F, Cl, Br or I, m=2 or 3, R 2Be NH (CH 2) nNR 4, NR 4Or NH (CH 2) n-Ar, R 3=CONH (CH 2) nNR 4The time, building-up process is:
The steps include: by before said process, obtain F-H1 after, earlier, obtain compound F 17-hydroxy-corticosterone-D2, F-D2 and different substituted amine compound (NH (CH with the condensation of 4-carbamoyl benzoate 2) nNR 4, NHR 4Or NH (CH 2) n-Ar) substitution reaction takes place, obtain compound F 17-hydroxy-corticosterone-D3, F-D3 again with different substituted amine compound (NH (CH 2) nNR 4) reaction, obtain title product (the described Quinzolone derivatives of claim 2) through column chromatography or recrystallization.
(5) as m=2 or 3, R 1=H, R 2=R 3=NHCO (CH 2) nNR 4; Perhaps R 2=H, R 1=R 3=NHCO (CH 2) nNR 4The time, building-up process is:
Figure GSA00000140984200061
The steps include: 4 or 5 substituted 2-benzaminic acid of nitro and various lactan pass ring, obtain compound 2.2 with the substituted phenyl aldehyde condensation of nitro, obtain compound 3, then through Na 2The S reduction obtains compound 4.4 with the substituted alkyl acyl chloride of chlorine [Cl (CH 2) nCOCl] carry out after alkylated reaction obtains midbody, again with substituted amine compound (NHR 4) effect and recrystallization obtain title product (the described Quinzolone derivatives of claim 3).
The present invention is open simultaneously and protected this Quinzolone derivatives in the purposes for preparing on the cancer therapy drug; And the cancer therapy drug that contains this Quinzolone derivatives.
Compared with prior art, the present invention has following beneficial effect:
(1) experiment proof; The disclosed novel quinazoline ketone derivatives of the present invention has very strong interaction with proto-oncogene DNA such as telomeric dna that is rich in guanine and c-myc; Demonstration has the good restraining activity to the telomere/Telomerase in the cancer cells; Expression to proto-oncogene c-myc has very strong restraining effect, shows significant antitumous effect, can be used for preparation and has the selectivity cancer therapy drug.
(2) further experiment proves, the novel quinazoline ketone derivatives that the present invention relates to has significant inhibitory effect to multiple JEG-3, and little to normal cytotoxicity, on the preparation cancer therapy drug, wide application space is arranged.
Embodiment
Below further specify technical scheme of the present invention through concrete embodiment.
Embodiment one: compound 2b's is synthetic
0.01mol exsiccant 4-nitro-2-benzaminic acid and 0.005mol Valerolactim are dissolved in the 250m1 toluene, drip the POCl3 of 3ml under the room temperature, refluxed 8 hours.Reaction solution is slowly poured in the frozen water, regulates pH to weakly alkaline, and suction filtration gets yellow solid.Filtrating is with (removal of solvent under reduced pressure merges gained solid before for 3 * 100mL) ethyl acetate extractions, collected organic layer, and bullion gets light yellow solid powder 2b through column chromatography purification (cyclohexane/ethyl acetate).
Productive rate: 37%; 1H NMR (400MHz, CDCl3) δ 8.44 (d, J=2.1Hz, 1H), 8.41 (d, J=8.8Hz, 1H), 8.17 (dd, J=8.8,2.1Hz, 1H), 4.10 (t, J=6.2Hz, 2H), 3.05 (t, J=6.6Hz, 2H), 2.10-1.95 (m, 4H); ESI-MS m/z:246 [M+H] +.
Figure GSA00000140984200071
Compound 2b
Embodiment two: compound 2e's is synthetic
Method is with embodiment one, and different is with 5-nitro-2-aminobenzoic acid substitution 4-nitro-2-benzaminic acid, gets faint yellow solid 2e.
Productive rate: 50%; 1H NMR (400MHz, CDCl3) δ 9.13 (d, J=2.6Hz, 1H), 8.50 (dd, J=9.0,2.6Hz, 1H), 7.71 (d, J=9.0Hz, 1H), 4.11 (t, J=6.2Hz, 2H), 3.06 (t, J=6.6Hz, 2H), 2.09-1.96 (m, 4H); ESI-MS m/z:246 [M+H] +.
Figure GSA00000140984200072
Compound 2e
Embodiment three: compound 2c's is synthetic
Method is with embodiment one, and different is to replace Valerolactim with hexanolactam, gets faint yellow solid 2c.
Productive rate: 25%; 1H NMR (400MHz, CDCl3) δ 8.41 (d, J=2.1Hz, 1H), 8.38 (d, J=8.8Hz, 1H), 8.16 (dd, J=8.8,2.1Hz, 1H), 4.46-4.36 (m, 2H), 3.17-3.07 (m, 2H), 1.97-1.80 (m, 6H); ESI-MS m/z:260 [M+H] +.
Figure GSA00000140984200081
Compound 2c
Embodiment four: compound 2f's is synthetic
Method is with embodiment one, and different is with 5-nitro-2-aminobenzoic acid substitution 4-nitro-2-benzaminic acid, and replaces Valerolactim with hexanolactam, gets faint yellow solid 2f.
Productive rate: 45%; 1H NMR (400MHz, CDCl3) δ 9.07 (d, J=2.6Hz, 1H), 8.47 (dd, J=9.0,2.6Hz, 1H), 7.68 (d, J=9.0Hz, 1H), 4.48-4.36 (m, 2H), 3.18-3.06 (m, 2H), 1.96-1.81 (m, 6H); ESI-MS m/z:260 [M+H] +.
Figure GSA00000140984200082
Compound 2f
Embodiment five: compound 3b's is synthetic
With 0.005mol compound 2b and 0.01mol 4-nitrobenzaldehyde, and 0.001mol NaOAc is dissolved in the 10ml acetate back flow reaction 8 hours; Reaction is chilled to room temperature after finishing; Suction filtration gets solid, and with chloroform (100ml) and acetone (200ml) washing, gets light yellow solid 3b.
Productive rate: 93%; 1H NMR (400MHz, DMSO) δ 8.45 (d, J=2.1Hz, 1H), 8.41-8.26 (m, 4H), 8.22 (dd, J=8.8,2.1Hz, 1H), 7.85 (d, J=8.7Hz, 2H), 4.15-4.04 (m, 2H), 3.00-2.88 (m, 2H), 2.07-1.94 (m, 2H); ESI-MS m/z:379 [M+H] +.
Figure GSA00000140984200083
Compound 3b
Embodiment six: compound 3e's is synthetic
Method is with embodiment five, and different is to replace compound 2b with compound 2e, gets faint yellow solid 3e.
Productive rate: 93%; 1H NMR (400MHz, DMSO) δ 8.84 (d, J=2.4Hz, 1H), 8.56 (dd, J=9.0,2.4Hz; 1H), 8.37 (s, 1H), 8.31 (d, J=8.7Hz, 2H); 7.90 (d, J=9.0Hz, 1H), 7.85 (d, J=8.7Hz, 2H); 4.13-4.05 (m, 2H), 2.98-2.91 (m, 2H), 2.04-1.96 (m, 2H); ESI-MS m/z:379 [M+H] +.
Figure GSA00000140984200091
Compound 3e
Embodiment seven: compound 3c's is synthetic
Method is with embodiment five, and different is to replace compound 2b with compound 2c, gets faint yellow solid 3c.
Productive rate: 42%; 1H NMR (400MHz, CDCl3) δ 8.60 (d, J=2.1Hz, 1H), 8.47 (d, J=8.7Hz, 1H); 8.30 (d, J=8.7Hz, 2H), 8.26 (dd, J=8.7,2.1Hz; 1H), 7.67 (d, J=8.7Hz, 2H), 7.23 (s, 1H); 4.38-4.30 (m, 2H), 2.87-2.79 (m, 2H), 2.03-1.90 (m, 4H); ESI-MS m/z:393 [M+H] +.
Figure GSA00000140984200092
Compound 3c
Embodiment eight: compound 3f's is synthetic
Method is with embodiment five, and different is to replace compound 2b with compound 2f, gets faint yellow solid 3f.
Productive rate: 40%; 1H NMR (400MHz, CDCl3) δ 9.16 (d, J=2.6Hz, 1H), 8.55 (dd, J=8.9,2.6Hz; 1H), 8.30 (d, J=8.7Hz, 2H), 7.86 (d, J=8.9Hz; 1H), 7.67 (d, J=8.7Hz, 2H), 7.25 (s, 1H); 4.38-4.32 (m, 2H), 2.88-2.81 (m, 2H), 2.04-1.90 (m, 4H); ESI-MS m/z:393 [M+H] +.
Figure GSA00000140984200101
Compound 3f
Embodiment nine: compound 4b's is synthetic
3b is dissolved in 50ml ethanol with the 0.005mol compound, and past adding is dissolved with the 80ml aqueous solution of 0.02mol nine water cure sodium and 0.05mol sodium hydroxide, refluxes 6 hours, and ethanol is removed in decompression, is cooled to 0-5 ℃, and suction filtration obtains the thick product of garnet after the washing repeatedly.Thick product is used the ethanol/acetone recrystallization, gets orange red solid 4b.
Productive rate: 91%; 1H NMR (400MHz, DMSO) δ 7.91 (s, 1H), 7.73 (d, J=8.6Hz, 1H), 7.27 (d; J=8.5Hz, 2H), 6.65 (dd, J=8.6,2.1Hz, 1H), 6.61 (d; J=8.5Hz, 2H), 6.60-6.57 (m, 1H), 5.96 (s, 2H), 5.57 (s; 2H), and 4.00-3.90 (m, 2H), 2.87-2.78 (m, 2H), 1.93-1.83 (m, 2H); ESI-MS m/z:319 [M+H] +.
Compound 4b
Embodiment ten: compound 4e's is synthetic
Method is with embodiment nine, and different is to replace compound 3b with compound 3e, gets faint yellow solid 4e.
Productive rate: 90%; 1H NMR (400MHz, DMSO) δ 7.83 (d, J=2.0Hz, 1H), 7.38 (d, J=8.7Hz, 1H), 7.24 (d; J=8.5Hz, 2H), 7.18 (s, 1H), 7.07 (dd, J=8.7,2.0Hz; 1H), 6.61 (d, J=8.5Hz, 2H), 5.55 (s, 2H), 5.51 (s; 2H), and 4.05-3.95 (m, 2H), 2.87-2.79 (m, 2H), 1.94-1.84 (m, 2H); ESI-MS m/z:319 [M+H] +.
Figure GSA00000140984200111
Compound 4e
Embodiment 11: compound 4c's is synthetic
Method is with embodiment nine, and different is to replace compound 3b with compound 3c, gets faint yellow solid 4c.
Productive rate: 60%; 1H NMR (400MHz, DMSO) δ 7.76 (d, J=8.6Hz, 1H), 7.25 (d, J=8.6Hz, 2H); 6.79 (s, 1H), 6.70 (dd, J=8.6,2.2Hz, 1H); 6.64-6.59 (m, 3H), 6.03 (s, 2H), 5.44 (s, 2H); 4.09-4.03 (m, 2H), 2.70-2.64 (m, 2H), 1.80-1.67 (m, 4H); ESI-MS m/z:333 [M+H] +.
Figure GSA00000140984200112
Compound 4c
Embodiment 12: Compound P-a1's is synthetic
0.0005mol compound 4b is suspended in the 2-chloroacetyl chloride of 10ml, back flow reaction 4 hours, after reaction was accomplished, cooling was put 0-5 ℃; Suction filtration, solid gets the alkylation midbody with ether washing 2 times, this midbody and 50mg KI is suspended in the 5ml ethanol again; Past Dropwise 5 ml is dissolved with the ethanol of 0.005mol Pyrrolidine, and back flow reaction 3 hours adds 20ml water, is cooled to 0 ℃; Suction filtration, with the ether washing, bullion is used the chloroform/ethanol recrystallization, obtains light yellow solid powder P-a1.
Productive rate: 60%; 1H NMR (400MHz, CDCl 3) δ (ppm): 9.45 (s, 1H), 9.25 (s, 1H), 8.18-8.26 (m, 2H), 7.96 (d; J=1.8Hz, 1H), 7.62-7.71 (m, 3H), 7.48 (d, J=8.5Hz, 2H); 4.19-4.11 (m, 2H), 3.33 (d, J=9.2Hz, 4H), 2.90-3.00 (m, 2H); 2.63-2.80 (m, 8H), 1.98-2.08 (m, 2H), 1.82-1.94 (m, 8H); ESI-MS m/z:541 [M+H] +.
Figure GSA00000140984200121
Compound P-a1
Embodiment 13: Compound P-a2's is synthetic
Method is with embodiment 13, and different is to replace Pyrrolidine with piperidines, gets faint yellow solid P-a2.Productive rate: 62%; 1H NMR (400MHz, CDCl 3) δ=9.64 (s, 1H), 9.43 (s, 1H), 8.26-8.18 (m, 2H), 7.93 (d, J=2.0Hz; 1H), 7.71-7.62 (m, 3H), 7.48 (d, J=8.6Hz, 2H), 4.20-4.11 (m, 2H); 3.12 (d, J=7.9Hz, 4H), 2.96 (t, J=5.5Hz, 2H), 2.68-2.48 (m; 8H), and 2.09-1.99 (m, 2H), 1.71-1.65 (m, 8H), 1.56-1.46 (m, 4H); ESI-MS m/z:569 [M+H] +.
Figure GSA00000140984200122
Compound P-a2
Embodiment 14: Compound P-a3's is synthetic
Method is with embodiment 13, and different is to replace Pyrrolidine with diethylamine, gets faint yellow solid P-a3.
Productive rate: 58%; 1H NMR (400MHz, CDCl 3) δ=9.74 (s, 1H), 9.54 (s, 1H), 8.26-8.18 (m, 2H), 7.93 (s; 1H), 7.71-7.63 (m, 3H), 7.48 (d, J=8.2,2H), 4.18-4.11 (m; 2H), 3.21 (s, 4H), 2.96 (t, J=6.1,2H), 2.77-2.60 (m; 8H), 2.07-1.99 (m, 2H), 1.12 (t, J=6.9,12H); ESI-MS m/z:545 [M+H] +.
Figure GSA00000140984200131
Compound P-a3
Embodiment 15: Compound P-b1's is synthetic
Method is with embodiment 13, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, gets faint yellow solid P-b1.
Productive rate: 73%; 1H NMR (400MHz, CDCl3) δ=11.68 (s, 1H), 11.45 (s, 1H), 8.23-8.13 (m, 2H), 7.83 (d; J=1.8,1H), 7.62-7.51 (m, 3H), 7.45 (d, J=8.5,2H), 4.18-4.10 (m; 2H), 2.95 (t, J=5.6,2H), 2.92-2.84 (m, 4H), 2.78-2.65 (m; 8H), and 2.61-2.53 (m, 4H), 2.06-2.00 (m, 2H), 1.98-1.88 (m, 8H); ESI-MS m/z:569 [M+H] +.
Figure GSA00000140984200132
Compound P-a1
Embodiment 16: Compound P-b2's is synthetic
Method is with embodiment 13, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces Pyrrolidine with piperidines, gets faint yellow solid P-b2.
Productive rate: 76%; 1H NMR (400MHz, CDCl 3) δ=11.77 (s, 1H), 11.60 (s, 1H), 8.23-8.14 (m, 2H), 7.97-7.90 (m; 1H), 7.66-7.55 (m, J=8.5Hz, 3H), 7.47 (d, J=8.5Hz, 2H); 4.18-4.11 (m, 2H), 2.96 (t, J=5.7Hz, 2H), 2.80-2.46 (m, 16H); 2.07-2.01 (m, 2H), 1.81-1.70 (m, 8H), 1.67-1.50 (m, 4H); ESI-MS m/z:597 [M+H] +.
Figure GSA00000140984200141
Compound P-b2
Embodiment 17: Compound P-b3's is synthetic
Method is with embodiment 13, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces Pyrrolidine with diethylamine, gets faint yellow solid P-b3.
Productive rate: 70%; 1H NMR (400MHz, CDCl 3) δ=11.69 (s, 1H), 11.45 (s, 1H), 8.19 (d, J=8.7,1H), 8.16 (s, 1H), 7.85 (d; J=1.8,1H), 7.63 (dd, J=8.7,1.8,1H), 7.60 (d, J=8.6,1H); 7.45 (d, J=8.6,1H), 4.18-4.10 (m, 2H), 2.95 (t, J=5.5,2H), 2.86-2.78 (m; 4H), and 2.78-2.66 (m, 4H), 2.61-2.51 (m, 4H), 2.05-1.98 (m, 2H), 1.24-1.10 (m, 12H); ESI-MS m/z:573 [M+H] +.
Figure GSA00000140984200142
Compound P-b3
Embodiment 18: compound M-a1's is synthetic
Method is with embodiment 13, and different is to replace 4b with 4e, gets faint yellow solid M-a1.
Productive rate: 52%; 1H NMR (400MHz, CDCl 3) δ=9.46 (s, 1H), 9.26 (s, 1H), 8.41 (dd, J=8.9,2.3,1H), 8.15 (s; 1H), 8.07 (d, J=2.3,1H), 7.72 (d, J=8.9,1H), 7.66 (d, J=8.5; 2H), 7.47 (d, J=8.5,2H), 4.23-4.12 (m, 2H), 3.38-3.27 (m, 4H), 2.97 (t; J=5.6,2H), 2.81-2.67 (m, 8H), 2.11-1.98 (m, 2H), 1.94-1.86 (m, 8H); ESI-MSm/z:541 [M+H] +.
Figure GSA00000140984200151
Compound M-a1
Embodiment 19: compound M-a2's is synthetic
Method is with embodiment 13, and different is to replace 4b with 4e, and replaces Pyrrolidine with piperidines, gets faint yellow solid M-a2.
Productive rate: 53%; 1H NMR (400MHz, CDCl 3) δ=9.61 (s, 1H), 9.46 (s, 1H), 8.39 (dd, J=8.9,2.3,1H), 8.16 (s, 1H); 8.09 (s, J=2.3,1H), 7.72 (d, J=8.9,1H), 7.66 (d, J=8.5,2H); 7.48 (d, J=8.5,2H), 4.21-4.14 (m, 2H), 3.23-3.07 (m, 4H), 2.97 (t, J=5.6; 2H), and 2.69-2.52 (m, 8H), 2.08-2.00 (m, 2H), 1.77-1.64 (m, 8H), 1.57-1.48 (m, 4H); ESI-MS m/z:569 [M+H] +.
Figure GSA00000140984200152
Compound M-a2
Embodiment 20: compound M-a3's is synthetic
Method is with embodiment 13, and different is to replace 4b with 4e, and replaces Pyrrolidine with diethylamine, gets faint yellow solid M-a3.
Productive rate: 50%; 1H NMR (400MHz, CDCl 3) δ=9.72 (s, 1H), 9.54 (s, 1H), 8.41 (dd, J=8.9,2.3,1H), 8.16 (s; 1H), 8.06 (s, J=2.3,1H), 7.73 (d, J=8.9,1H), 7.66 (d, J=8.6; 2H), 7.48 (d, J=8.6,2H), 4.20-4.13 (m, 2H), 3.25-3.12 (m, J=4.5,4H); 3.00-2.93 (m, 2H), 2.74-2.61 (m, 8H), 2.08-1.99 (m, 2H), 1.15-1.08 (m, 12H); ESI-MS m/z:545 [M+H] +.
Compound M-a3
Embodiment 21: compound M-b1's is synthetic
Method is with embodiment 13, and different is to replace 4b with 4e, and replaces the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, gets faint yellow solid M-b1.
Productive rate: 65%; 1H NMR (400MHz, CDCl3) δ=11.56 (s, 1H), 11.45 (s, 1H), 8.24 (dd, J=8.8Hz, 1.9Hz, 1H), 8.13 (s; 1H), 8.01 (d, J=1.9Hz, 1H), 7.69 (d, J=8.8Hz, 1H), 7.55 (d, J=8.4Hz; 2H), 7.44 (d, J=8.4Hz, 2H), 4.22-4.09 (m, 2H), 3.01-2.93 (m, 2H), 2.93-2.83 (m; 4H), and 2.78-2.65 (m, 8H), 2.63-2.52 (m, 4H), 2.06-1.99 (m, 2H), 1.96-1.89 (m, 8H); ESI-MS m/z:569 [M+H] +.
Figure GSA00000140984200162
Compound M-b1
Embodiment 22: compound M-b2's is synthetic
Method is with embodiment 13, and different is to replace 4b with 4e, replaces the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces Pyrrolidine with piperidines, gets faint yellow solid M-b2.
Productive rate: 67%; 1H NMR (400MHz, CDCl 3) δ=11.71 (s, 1H), 11.55 (s, 1H), 8.28 (dd, J=8.9,2.1,1H), 8.13 (s; 1H), 8.09 (s, J=2.1,1H), 7.70 (d, J=8.9,1H), 7.61 (d, J=8.4; 2H), 7.45 (d, J=8.4,2H), 4.22-4.10 (m, 2H), 2.96 (t, J=6.0,2H); 2.78-2.43 (m, 16H), 2.07-1.99 (m, 2H), 1.80-1.70 (m, 8H), 1.64-1.53 (m, 4H); ESI-MS m/z:597 [M+H] +.
Figure GSA00000140984200163
Compound M-b2
Embodiment 23: compound M-b3's is synthetic
Method is with embodiment 13, and different is to replace 4b with 4e, replaces the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces Pyrrolidine with diethylamine, gets faint yellow solid M-b3.
Productive rate: 64%; 1H NMR (400MHz, CDCl 3) δ=11.61 (s, 1H), 11.47 (s, 1H), 8.29 (dd, J=8.9,2.3,1H), 8.13 (s, 1H); 8.04 (d, J=2.3,1H), 7.69 (d, J=8.9,1H), 7.59 (d, J=8.5,2H); 7.44 (d, J=8.5,2H), 4.19-4.11 (m, 2H), 2.95 (t, J=5.8,2H), 2.84-2.76 (m; 4H), and 2.76-2.65 (m, 8H), 2.59-2.49 (m, 4H), 2.07-1.98 (m, 2H), 1.22-1.11 (m, 12H); ESI-MS m/z:573 [M+H] +.
Figure GSA00000140984200171
Compound M-b3
Embodiment 24: Compound P-h1's is synthetic
Method is with embodiment 13, and different is to replace 4b with 4c, replaces the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, gets yellow solid P-h1.
Productive rate: 57%; 1H NMR (400MHz, CDCl 3) δ 11.61 (s, 1H), 11.32 (s, 1H), 8.14 (d, J=8.7Hz, 1H), 7.70 (d; J=8.7Hz, 1H), 7.66 (s, 1H), 7.47 (d, J=8.4Hz, 2H), 7.38 (d; J=8.4Hz, 2H), 6.98 (s, 1H), 4.27-4.16 (m, 2H), 2.85-2.77 (m, 4H); 2.76-2.70 (m, 2H), 2.68-2.59 (m, 8H), 2.53-2.47 (m, 4H), 1.89-1.77 (m, 12H); ESI-MS m/z:583 [M+H] +.
Figure GSA00000140984200172
Compound P-h1
Embodiment 25: Compound P-h2's is synthetic
Method is with embodiment 13, and different is to replace 4b with 4c, replaces the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces Pyrrolidine with piperidines, gets yellow solid P-h2.
Productive rate: 56%; 1H NMR (400MHz, CDCl 3) δ 11.72 (s, 1H), 11.53 (s, 1H), 8.23 (d, J=8.7Hz, 1H), 7.84 (s, 1H); 7.77 (s, J=8.7Hz, 1H), 7.60 (d, J=8.3Hz, 2H), 7.47 (d, J=8.3Hz, 2H); 7.07 (s, 1H), 4.33-4.24 (m, 2H), 2.86-2.79 (m, 2H), 2.72-2.66 (m, 4H); 2.65-2.48 (m, 12H), 1.95-1.85 (m, 4H), 1.77-1.70 (m, 8H), 1.62-1.53 (m, 4H); ESI-MS m/z:611 [M+H] +.
Figure GSA00000140984200181
Compound P-h2
Embodiment 26: compound F 17-hydroxy-corticosterone-I1's is synthetic
With 5.19g exsiccant 4,5-difluoro anthranilic acid (30mmol) is dissolved in the 500ml exsiccant toluene with 7.65g pyrrolidone (90mmol), drips the POCl3 of 15ml under the room temperature, refluxes 8 hours.After the cooling, reaction solution is slowly poured in an amount of frozen water, is alkalescence with the ammoniacal liquor regulator solution, and suction filtration is collected solid, behind the solid drying, uses the acetone heating for dissolving, and suction filtration discards insoluble solids, and concentrating under reduced pressure acetone waits the thick product of part.Toluene layer is collected in the filtrating extraction, and vacuum rotary steam behind the anhydrous magnesium sulfate drying also obtains the thick product of part.After the thick product of two portions merges, pass through the silica gel column chromatography purifying as eluent, obtain light grey to white solid F-I1 with petrol ether/ethyl acetate (volume ratio 4/1).
Productive rate be 56%:1H NMR (400MHz, CDCl3) δ 8.02 (dd, J=10.0,8.6Hz, 1H), 7.42 (dd, J=10.8,7.0Hz, 1H), 4.21 (t, J=8.0Hz, 2H), 3.18 (t, J=8.0Hz, 2H), 2.35-2.27 (m, 2H); LC-MS m/z:223 [M+H] +.
Compound F 17-hydroxy-corticosterone-I1
Embodiment 27: compound F 17-hydroxy-corticosterone-I2's is synthetic
1.11g exsiccant F-I1 (5mmol) is dissolved among the DMF of 18ml with the N methyl piperazine (22.5mmol) of 2.5ml, adds the yellow soda ash of catalytic amount, 140 ℃ were reacted 2 hours; The decompression rotary evaporation is removed part DMF, then solution is poured in the 30ml water into suction filtration; Get white solid; With water washing repeatedly, drying gets white solid.
Productive rate 87%:1H NMR (400MHz, CDCl3) δ 7.82 (d, J=13.0Hz, 1H), 7.08 (d, J=7.8Hz; 1H), 4.18 (t, J=8.0Hz, 2H), 3.30 (t, J=4.0Hz; 4H), 3.14 (t, J=8.0Hz, 2H), 2.64 (t, J=4.0Hz; 4H), 2.38 (s, 3H), 2.31-2.24 (m, 2H); LC-MS m/z:303 [M+H] +.
Figure GSA00000140984200191
Compound F 17-hydroxy-corticosterone-I2
Embodiment 28: compound F 17-hydroxy-corticosterone-I3's is synthetic
3.02g exsiccant F-I2 (10mmol) and 3.02g paranitrobenzaldehyde (20mmol) mixed dissolution in 70ml acetate, are added the sodium acetate of catalytic amount, 115 ℃ of back flow reaction 6 hours; Part acetate is removed in decompression, adds 15ml acetone, is cooled to 0-5 ℃; Suction filtration; Solid with twice of 15ml washing with acetone after, drying, yellow powder shape solid.
Productive rate 78%:1H NMR (400MHz, CDCl3) δ 8.31 (d, J=8.8Hz, 2H), 7.88 (d, J=13.0Hz, 1H); 7.84 (s, 1H), 7.70 (d, J=8.8Hz, 2H), 7.19 (d; J=7.8Hz, 1H), 4.32 (t, J=8.0Hz, 2H), 3.37-3.33 (m; 6H), 2.69 (t, J=4.0Hz, 4H), 2.41 (s, 3H); LC-MSm/z:436 [M+H] +.
Figure GSA00000140984200192
Compound F 17-hydroxy-corticosterone-I3
Embodiment 29: compound F 17-hydroxy-corticosterone-I4's is synthetic
1.74g F-I3 (4mmol) is dissolved in 40ml ethanol; Toward wherein adding the 60ml aqueous solution that is dissolved with 2.88g nine water cure sodium (12mmol) and 2.4g sodium hydroxide (60mmol); 90 ℃ were refluxed 6 hours, and the decompression rotary evaporation is removed most of second alcohol and water, is chilled to room temperature; Suction filtration obtains the red-brown product after the washing repeatedly.Thick product passes through purification by silica gel column chromatography with methyl alcohol/chloroform (volume ratio 1/50 to 1/10) as eluent, obtains orange/yellow solid.
Productive rate 84%:1H NMR (400MHz, CDCl3) δ 7.83 (d, J=13.0Hz, 1H), 7.69 (s, 1H), 7.40 (d, J=8.4Hz; 2H), 7.15 (d, J=7.8Hz, 1H), 6.72 (d, J=8.5Hz, 2H), 4.25 (t; J=8.0Hz, 2H), 3.95 (s, 2H), 3.31 (t, J=4.0Hz, 4H), 3.25 (t; J=6.2Hz, 2H), 2.64 (t, J=4.0Hz, 4H), 2.39 (s, 3H); LC-MS m/z:406 [M+H] +.
Compound F 17-hydroxy-corticosterone-I4
Embodiment 30: compound F 17-hydroxy-corticosterone-H1's is synthetic
Method is with embodiment 27, and the raw material that closes ring has changed Valerolactim into by pyrrolidone, obtains grey to white solid F-H1.
Productive rate 58%:1H NMR (400MHz, DMSO) δ 7.98 (dd, J=9.9,9.4Hz, 1H), 7.63 (dd, J=11.5,7.3Hz, 1H), 3.93 (t, J=6.2Hz, 2H), 2.90 (t, J=6.6Hz, 2H), 1.99-1.88 (m, 2H), 1.87-1.74 (m, 2H); LC-MS m/z:237 [M+H] +.
Figure GSA00000140984200202
Compound F 17-hydroxy-corticosterone-H1
Embodiment hentriaconta-: compound F 17-hydroxy-corticosterone-H2's is synthetic
Method is with embodiment 29, and different is to replace F-I2 with F-H1, gets yellow solid.
Productive rate 83%:1H NMR (400MHz, DMSO) δ 8.30 (d, J=8.7Hz, 2H), 8.21 (s, 1H), 8.09-8.02 (m, 1H), 7.86-7.75 (m, 3H), 4.06 (t, J=6.0Hz, 2H), 2.92 (t, J=5.4Hz, 2H), 2.01-1.94 (m, 2H); LC-MS m/z:370 [M+H] +.
Compound F 17-hydroxy-corticosterone-H2
Embodiment 32: compound F 17-hydroxy-corticosterone-H3's is synthetic
Method is with embodiment 30, and different is to replace F-I3 with F-H2, and solvent replaces ethanol with acetonitrile, gets yellow solid.
Productive rate 91%:1H NMR (400MHz, CDCl3) δ 8.12 (s, 1H), 8.00 (dd, J=10.0,8.7Hz; 1H), 7.54-7.44 (m, 1H), 7.37 (d, J=8.5Hz, 2H); 6.72 (d, J=8.6Hz, 2H), 4.16-4.11 (m, 2H), 3.97 (br; 2H), and 2.99-2.92 (m, 2H), 2.08-1.98 (m, 2H); LC-MS m/z:340 [M+H] +..
Figure GSA00000140984200212
Compound F 17-hydroxy-corticosterone-H3
Embodiment 33: compound F 17-hydroxy-corticosterone-H4's is synthetic
Method is with embodiment 28, and different is to replace F-I1 with F-H3, and replaces DMF to make solvent with DMSO, gets yellow solid.
Productive rate 87%:1H NMR (400MHz, CDCl3) δ 8.04 (s, 1H), 7.81 (d, J=13.0Hz, 1H), 7.34 (d, J=8.5Hz; 2H), 7.13 (d, J=7.9Hz, 1H), 6.71 (d, J=8.5Hz, 2H), 4.12 (t; J=6.0Hz, 2H), 3.88 (s, 2H), 3.33 (br, 4H), 2.94 (t, J=5.6Hz; 2H), 2.68 (br, 4H), 2.41 (s, 3H), 2.05-1.97 (m, 2H); LC-MS m/z:420 [M+H] +.
Figure GSA00000140984200221
Compound F 17-hydroxy-corticosterone-H4
Embodiment 34: compound F 17-hydroxy-corticosterone P-a1's is synthetic
0.81g F-I4 (2mmol) is suspended in the 2-chloroacetyl chloride of 7ml, back flow reaction 4 hours, system are cooled to 0-5 ℃; Suction filtration, solid respectively washs 3 times with 15ml chloroform and 15ml ether, obtains the 0.91g yellow solid; Get this midbody of 0.5mmol and catalytic amount Soiodin and join in the absolute ethyl alcohol of 5ml, be heated to backflow, toward Pyrrolidine and the 2ml alcoholic acid mixing solutions of system Dropwise 5 mmol; Back flow reaction 4 hours adds a small amount of ether, is cooled to 0 ℃; Suction filtration with the ether washing repeatedly, gets thick product.Thick product is through purification by silica gel column chromatography, eluent be chloroform/methanol=500/1 to 50/1, can get light yellow solid after the purifying.
Productive rate 30%:1H NMR (400MHz, CDCl3) δ 9.29 (s, 1H), 7.85 (d, J=13.0Hz, 1H), 7.76 (s; 1H), 7.69 (d, J=8.5Hz, 2H), 7.54 (d, J=8.6Hz, 2H); 7.17 (d, J=7.8Hz, 1H), 4.28 (t, J=7.2Hz, 2H), 3.41-3.23 (m; 8H), 2.80-2.62 (m, 8H), 2.41 (s, 3H), 1.89 (s, 4H); LC-MS m/z:517 [M+H] +.
Compound F 17-hydroxy-corticosterone P-a1
Embodiment 35: compound F 17-hydroxy-corticosterone P-a2's is synthetic
Method is with embodiment 35, and different is to replace Pyrrolidine with diethylamine, gets light yellow solid.
Productive rate 33%:1H NMR (400MHz, CDCl3) δ 9.59 (s, 1H), 7.86 (d, J=12.9Hz, 1H), 7.76 (s, 1H), 7.69 (d; J=8.4Hz, 2H), 7.55 (d, J=8.4Hz, 2H), 7.18 (d, J=7.8Hz, 1H), 4.28 (t; J=7.1Hz, 2H), 3.38 (s, 4H), 3.30 (t, J=6.0Hz, 2H), 3.19 (s; 2H), 2.84-2.61 (m, 8H), 2.46 (s, 3H), 1.11 (t, J=7.1Hz, 6H); LC-MS m/z:519 [M+H] +.
Figure GSA00000140984200231
Compound F 17-hydroxy-corticosterone P-a2
Embodiment 36: compound F 17-hydroxy-corticosterone P-a3's is synthetic
Method is with embodiment 35, and different is to replace Pyrrolidine with piperidines, gets light yellow solid.
Productive rate 52%:1H NMR (400MHz, CDCl3) δ 9.45 (s, 1H), 7.85 (d, J=12.9Hz, 1H), 7.76 (s, 1H), 7.68 (d; J=8.6Hz, 2H), 7.55 (d, J=8.7Hz, 2H), 7.17 (d, J=7.8Hz, 1H), 4.28 (t; J=8.0Hz, 2H), 3.39-3.25 (m, 6H), 3.11 (s, 2H), 2.68 (s, 4H), 2.57 (t; J=4.0Hz, 4H), 2.41 (s, 3H), 1.70-1.64 (m, 4H), 1.51-1.46 (m, 2H); LC-MS m/z:531 [M+H] +.
Figure GSA00000140984200232
Compound F 17-hydroxy-corticosterone P-a3
Embodiment 37: compound F 17-hydroxy-corticosterone P-a4's is synthetic
Method is with embodiment 35, and different is to replace F-I4 with F-H4, gets light yellow solid.
Productive rate 29%:1H NMR (400MHz, CDCl3) δ 9.24 (s, 1H), 8.12 (s, 1H), 7.82 (d, J=13.0Hz, 1H), 7.66 (d, J=8.6Hz; 2H), 7.47 (d, J=8.6Hz, 2H), 7.15 (d, J=7.8Hz, 1H), 4.14 (t, J=6.0Hz; 2H), 3.36-3.26 (m, 6H), 2.96 (t, J=5.5Hz, 2H), 2.72 (t, J=5.2Hz, 4H); 2.66 (t, J=4.0Hz, 4H), 2.40 (s, 3H), 2.05-2.00 (m, 2H), 1.91-1.87 (m, 4H); LC-MS m/z:531 [M+H] +.
Figure GSA00000140984200241
Compound F 17-hydroxy-corticosterone P-a4
Embodiment 38: compound F 17-hydroxy-corticosterone P-a5's is synthetic
Method is with embodiment 35, and different is to replace F-I4 with F-H4, and replaces Pyrrolidine with diethylamine, gets light yellow solid.
Productive rate 30%:1H NMR (400MHz, CDCl3) δ 9.53 (s, 1H), 8.11 (s, 1H), 7.82 (d, J=12.9Hz, 1H), 7.65 (d, J=8.6Hz; 2H), 7.47 (d, J=8.5Hz, 2H), 7.15 (d, J=7.9Hz, 1H), 4.13 (t, J=6.0Hz; 2H), 3.32 (t, J=4.0Hz, 4H), 3.17 (s, 2H), 2.95 (t, J=5.6Hz, 2H); 2.70-2.62 (m, 3H), 2.39 (s, 3H), 2.05-1.98 (m, 2H), 1.11 (t, J=7.1Hz, 6H); LC-MS m/z:533 [M+H] +.
Figure GSA00000140984200242
Compound F 17-hydroxy-corticosterone P-a5
Embodiment 39: compound F 17-hydroxy-corticosterone P-a6's is synthetic
Method is with embodiment 35, and different is to replace F-I4 with F-H4, and replaces Pyrrolidine with piperidines, gets light yellow solid.
Productive rate 41%:1H NMR (400MHz, CDCl3) δ 9.40 (s, 1H), 8.11 (s, 1H), 7.81 (d, J=12.9Hz, 1H), 7.64 (d, J=8.5Hz; 2H), 7.47 (d, J=8.5Hz, 2H), 7.14 (d, J=7.8Hz, 1H), 4.13 (t, J=6.0Hz, 2H); 3.31 (t, J=4.0Hz, 4H), 3.10 (s, 2H), 2.94 (t, J=6.0Hz, 2H), 2.65 (br, 4H); 2.56 (br, 4H), 2.39 (s, 3H), 2.04-2.00 (m, 2H), 1.70-1.63 (m, 4H), 1.54-1.48 (m, 2H); LC-MS m/z:545 [M+H] +.
Figure GSA00000140984200251
Compound F 17-hydroxy-corticosterone P-a6
Embodiment 40: compound F 17-hydroxy-corticosterone P-b1's is synthetic
Method is with embodiment 35, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, gets light yellow solid.
Productive rate 18%:1H NMR (400MHz, CDCl3) δ 11.43 (s, 1H), 7.76 (d, J=13.0Hz, 1H), 7.66 (br, 1H), 7.51 (d, J=8.6Hz; 2H), 7.43 (d, J=8.6Hz, 2H), 7.08 (d, J=7.8Hz, 1H), 4.19 (t, J=7.2Hz; 2H), 3.27-3.17 (m, 6H), 2.81 (t, J=6.0Hz, 2H), 2.64 (br, 4H), 2.56 (br; J=4.3Hz, 4H), 2.50 (t, J=6.0Hz, 2H), 2.30 (s, 3H), 1.85 (br, 4H); LC-MS m/z:531 [M+H] +.
Figure GSA00000140984200252
Compound F 17-hydroxy-corticosterone P-b1
Embodiment 41: compound F 17-hydroxy-corticosterone P-b2's is synthetic
Method is with embodiment 35, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces Pyrrolidine with diethylamine, gets light yellow solid.
Productive rate 34%:1H NMR (400MHz, CDCl3) δ 11.56 (s, 1H), 7.81 (d, J=12.9Hz, 1H), 7.72 (s, 1H), 7.62 (d; J=8.6Hz, 2H), 7.50 (d, J=8.6Hz, 2H), 7.14 (d, J=7.8Hz, 1H), 4.25 (t; J=7.2Hz, 2H), 3.31 (t, J=6.0Hz, 4H), 3.26 (t, J=8.0Hz, 2H), 2.80 (t; J=6.0Hz, 2H), 2.70 (q, J=7.1Hz, 4H), 2.63 (t, J=4.0Hz, 4H); 2.53 (t, J=6.0Hz, 2H), 2.37 (s, 3H), 1.16 (t, J=7.1Hz, 6H); LC-MS m/z:533 [M+H] +.
Figure GSA00000140984200261
Compound F 17-hydroxy-corticosterone P-b2
Embodiment 42: compound F 17-hydroxy-corticosterone P-b3's is synthetic
Method is with embodiment 35, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces Pyrrolidine with piperidines, gets light yellow solid.
Productive rate 25%:1H NMR (400MHz, CDCl3) δ 11.62 (s, 1H), 7.83 (d, J=12.9Hz, 1H), 7.73 (s, 1H); 7.64 (d, J=8.1Hz, 2H), 7.51 (d, J=8.0Hz, 2H), 7.16 (d, J=7.5Hz; 1H), 4.26 (t, J=8.0Hz, 2H), 3.38-3.22 (m, 6H), 2.74-2.51 (m; 12H), 2.38 (s, 3H), 1.73 (br, 4H), 1.59 (br, 2H); LC-MS m/z:545 [M+H] +.
Compound F 17-hydroxy-corticosterone P-b3
Embodiment 43: compound F 17-hydroxy-corticosterone P-b4's is synthetic
Method is with embodiment 35, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces F-I4 with F-H4, gets light yellow solid.
Productive rate 31%:1H NMR (400MHz, CDCl3) δ 11.25 (s, 1H), 8.09 (s, 1H), 7.81 (d, J=13.0Hz, 1H), 7.57 (d; J=8.6Hz, 2H), 7.44 (d, J=8.5Hz, 2H), 7.14 (d, J=7.9Hz, 1H), 4.13 (t; J=6.0Hz, 2H), 3.31 (t, J=6.0Hz, 4H), 2.94 (t, J=5.7Hz, 4H), 2.77 (br; 4H), 2.67-2.59 (m, 6H), 2.38 (s, 3H), 2.04-1.99 (m, 2H), 1.94 (br, 4H); LC-MS m/z:545 [M+H] +.
Figure GSA00000140984200271
Compound F 17-hydroxy-corticosterone P-b4
Embodiment 44: compound F 17-hydroxy-corticosterone P-b5's is synthetic
Method is with embodiment 35, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces F-I4 with F-H4, and replaces Pyrrolidine with diethylamine, gets light yellow solid.
Productive rate 30%:1H NMR (400MHz, CDCl3) δ 11.42 (s, 1H), 8.09 (s, 1H), 7.81 (d, J=13.0Hz, 1H), 7.61 (d; J=8.5Hz, 2H), 7.44 (d, J=8.5Hz, 2H), 7.14 (d, J=7.8Hz, 1H), 4.13 (t; J=6.0Hz, 2H), 3.31 (t, 4H), 2.94 (t, J=5.7Hz, 2H), 2.83 (t, J=6.0Hz; 2H), 2.72 (q, J=14.3,7.1Hz, 4H), 2.64 (t, J=4.0Hz, 4H), 2.56 (t; J=4.0Hz, 2H), 2.38 (s, 3H), 2.03-1.98 (m, 2H), 1.17 (t, J=7.1Hz, 6H); LC-MS m/z:547 [M+H] +.
Figure GSA00000140984200272
Compound F 17-hydroxy-corticosterone P-b5
Embodiment 45: compound F 17-hydroxy-corticosterone P-b6's is synthetic
Method is with embodiment 35, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces F-I4 with F-H4, and replaces Pyrrolidine with piperidines, gets light yellow solid.
Productive rate 32%:1H NMR (400MHz, CDCl3) δ 11.48 (s, 1H), 8.09 (s, 1H), 7.81 (d, J=13.0Hz, 1H), 7.62 (d, J=8.5Hz; 2H), 7.44 (d, J=8.5Hz, 2H), 7.15 (d, J=7.9Hz, 1H), 4.13 (t, J=6.0Hz, 2H); 3.31 (t, J=4.0Hz, 4H), 2.95 (t, J=5.6Hz, 2H), 2.72 (t, J=6.0Hz, 2H), 2.68-2.50 (m; 10H), 2.38 (s, 3H), 2.05-1.99 (m, 2H), 1.78-1.70 (m, 4H), 1.58 (br, 2H); LC-MS m/z:559 [M+H] +.
Figure GSA00000140984200281
Compound F 17-hydroxy-corticosterone P-b6
Embodiment 46: compound F 17-hydroxy-corticosterone-C3's is synthetic
Method is with embodiment 29, and different is to use carboxyl benzaldehyde is replaced paranitrobenzaldehyde, obtains light yellow solid.
Productive rate 73%:1H NMR (400MHz, DMSO) δ 10.11 (s, 1H), 8.02 (d, J=8.6Hz, 2H), 7.79-7.73 (m, 3H); 7.71 (d, J=13.2Hz, 1H), 7.19 (d, J=8.1Hz, 1H), 4.17 (t, J=6.9Hz; 2H), 3.23 (br, 6H), 2.54 (br, 4H), 2.27 (s, 3H); LC-MS m/z:435 [M+H] +.
Figure GSA00000140984200282
Compound F 17-hydroxy-corticosterone-C3
Embodiment 47: compound F 17-hydroxy-corticosterone-D2's is synthetic
Method is with embodiment 29, and different is to use carboxyl benzaldehyde is replaced paranitrobenzaldehyde, and replaces F-I2 with F-H1, obtains light yellow solid.
Productive rate 75%:1H NMR (400MHz, DMSO) δ 10.11 (s, 0H), 8.18 (s, 1H), 8.05-8.00 (m, 3H), 7.76 (dd; J=11.4,7.3Hz, 1H), 7.65 (d, J=8.3Hz, 2H), 4.05 (t; J=6.0Hz, 2H), 2.92 (t, J=6.0Hz, 2H), 2.01-1.93 (m, 2H); LC-MS m/z:369 [M+H] +.
Figure GSA00000140984200283
Compound F 17-hydroxy-corticosterone-D2
Embodiment 48: compound F 17-hydroxy-corticosterone-D3's is synthetic
Method is with embodiment 28, and different is to replace F-I1 with F-D2, and replaces DMF with DMSO, obtains light yellow solid.
Productive rate 71%:1H NMR (400MHz, DMSO) δ 8.17 (s, 1H), 7.99 (d, J=8.3Hz, 2H), 7.67 (d, J=13.1Hz; 1H), 7.62 (d, J=8.3Hz, 2H), 7.15 (d, J=8.1Hz, 1H), 4.03 (t; J=6.0Hz, 2H), 3.21 (t, J=4.4Hz, 4H), 2.91 (t, J=6.0Hz; 2H), 2.54-2.51 (m, 4H), 2.25 (s, 3H), 1.98-1.92 (m, 2H); LC-MS m/z:449 [M+H] +.
Figure GSA00000140984200291
Compound F 17-hydroxy-corticosterone-D3
Embodiment 49: compound F 17-hydroxy-corticosterone P-C1's is synthetic
0.217g F-C3 (0.5mmol) is dissolved among the 4mlDMF, adds 0.14ml triethylamine (1mmmol), toward the 2-Pyrrolidine base ethamine (1mmol) that wherein drips 0.16ml; 0.33gBOP (0.75mmol) with the solution of 4mlDMF; 60 ℃ were reacted 3 hours, and most of DMF, water and dichloromethane extraction are removed in decompression; Concentrate organic phase, get thick product.Thick product is through purification by silica gel column chromatography, eluent be chloroform/methanol=500/1 to 50/1, can get light yellow solid after the purifying.
Productive rate 41%:1H NMR (400MHz, CDCl3) δ 7.75 (d, J=8.1Hz, 2H), 7.64-7.57 (m, 2H), 7.40 (d, J=8.1Hz, 2H); 7.23 (t, J=4.4Hz, 1H), 6.99 (d, J=7.7Hz, 1H), 4.09 (t, J=6.9Hz; 2H), and 3.53-3.47 (m, 2H), 3.24-3.18 (m, 4H), 3.12-3.05 (m, 2H), 2.67 (t; J=5.8Hz, 2H), 2.57-2.50 (m, 8H), 2.29 (s, 3H), 1.77-1.71 (m, 4H); LC-MS m/z:531 [M+H] +.
Figure GSA00000140984200301
Compound F 17-hydroxy-corticosterone P-C1
Embodiment 50: compound F 17-hydroxy-corticosterone P-C2's is synthetic
Method is with embodiment 50, and different is to replace 2-Pyrrolidine base ethamine with 2-diethylin ethamine, obtains light yellow solid.
Productive rate 44%: 1H NMR (400MHz, CDCl 3) δ 7.74 (d, J=8.3Hz, 2H), 7.63-7.58 (m, 2H), 7.42 (d, J=8.3Hz, 2H), 7.19 (t; J=4.8Hz, 1H), 6.99 (d, J=7.8Hz, 1H), 4.10 (t, J=7.1Hz, 2H), 3.46-3.40 (m; 2H), 3.23-3.18 (m, 4H), 3.09 (t, J=5.8Hz, 2H), 2.60 (t, J=6.0Hz; 2H), 2.55-2.48 (m, 8H), 2.28 (s, 3H), 0.98 (t, J=7.1Hz, 6H); LC-MSm/z:533 [M+H] +.
Compound F 17-hydroxy-corticosterone P-C2
Embodiment 51: compound F 17-hydroxy-corticosterone P-C3's is synthetic
Method is with embodiment 50, and different is to replace 2-Pyrrolidine base ethamine with the 2-dimethylaminoethylam,ne, obtains light yellow solid.
Productive rate 35%: 1H NMR (400MHz, CDCl 3) δ 7.66 (d, J=8.2Hz, 2H), 7.51-7.44 (m, 2H), 7.29 (d, J=8.3Hz, 2H); 7.16 (t, J=4.9Hz, 1H), 6.88 (d, J=7.8Hz, 1H), 3.97 (t, J=7.1Hz; 2H), 3.44-3.38 (m, 2H), 3.17-3.09 (m, 4H), 2.95 (t, J=5.7Hz, 2H); 2.50-2.41 (m, J=13.9,7.8Hz, 6H), 2.23 (s, 3H), 2.17 (s, 6H); LC-MSm/z:505 [M+H] +.
Figure GSA00000140984200311
Compound F 17-hydroxy-corticosterone P-C3
Embodiment 52: compound F 17-hydroxy-corticosterone P-C4's is synthetic
Method is with embodiment 50, and different is to replace 2-Pyrrolidine base ethamine with 2-piperidyl ethamine, obtains light yellow solid.
Productive rate 39%: 1H NMR (400MHz, CDCl 3) δ 7.80 (d, J=8.1Hz, 2H), 7.70-7.64 (m, J=13.0Hz, 2H), 7.47 (d, J=8.2Hz, 2H); 7.40 (t, J=4.3Hz, 1H), 7.05 (d, J=7.8Hz, 1H), 4.15 (t, J=7.0Hz, 2H); 3.54-3.49 (m, 2H), 3.27-3.22 (m, 4H), 3.17-3.14 (m, J=5.4Hz, 2H), 2.59-2.52 (m, 6H); 2.46-2.38 (m, 4H), 2.32 (s, 3H), 1.61-1.55 (m, 4H), 1.47-1.40 (m, 2H); LC-MSm/z:545 [M+H] +.
Figure GSA00000140984200312
Compound F 17-hydroxy-corticosterone P-C4
Embodiment 53: compound F 17-hydroxy-corticosterone P-C5's is synthetic
Method is with embodiment 50, and different is to replace F-C3 with F-D3, obtains light yellow solid.
Productive rate 30%: 1H NMR (400MHz, CDCl 3) δ 8.07 (s, 1H), 7.78 (d, J=8.2Hz, 2H), 7.70 (d, J=12.9Hz, 1H), 7.42 (d, J=8.2Hz; 2H), 7.11 (t, J=4.5Hz, 1H), 7.03 (d, J=7.8Hz, 1H), 4.02 (t, J=6.0Hz, 2H); 3.53-3.47 (m, 2H), 3.24-3.17 (m, 4H), 2.83 (t, J=5.3Hz, 2H), 2.65 (t, J=5.9Hz, 2H); 2.56-2.52 (m, 4H), 2.52-2.47 (m, 4H), 2.28 (s, 3H), 1.95-1.89 (m, 2H), 1.75-1.69 (m, 4H); LC-MSm/z:545 [M+H] +.
Figure GSA00000140984200321
Compound F 17-hydroxy-corticosterone P-C5
Embodiment 54: compound F 17-hydroxy-corticosterone P-C6's is synthetic
Method is with embodiment 50, and different is to replace F-C3 with F-D3, and replaces 2-Pyrrolidine base ethamine with 2-diethylin ethamine, obtains light yellow solid.
Productive rate 28%: 1H NMR (400MHz, CDCl 3) δ 8.08 (s, 1H), 7.78 (d, J=8.2Hz, 2H), 7.70 (d, J=12.9Hz, 1H), 7.43 (d, J=8.2Hz; 2H), 7.21 (t, J=4.5Hz, 1H), 7.04 (d, J=7.8Hz, 1H), 4.03 (t, J=4.0Hz, 2H); 3.47-3.42 (m, 2H), 3.24-3.18 (m, 4H), 2.84 (t, J=5.4Hz, 2H), 2.61 (t, J=5.9Hz, 2H); 2.56-2.49 (m, 8H), 2.29 (s, 3H), 1.96-1.89 (m, 2H), 0.99 (t, J=7.1Hz, 6H); LC-MSm/z:547 [M+H] +.
Figure GSA00000140984200322
Compound F 17-hydroxy-corticosterone P-C6
Embodiment 55: compound F 17-hydroxy-corticosterone P-C7's is synthetic
Method is with embodiment 50, and different is to replace F-C3 with F-D3, and replaces 2-Pyrrolidine base ethamine with the 2-dimethylaminoethylam,ne, obtains light yellow solid.
Productive rate 33%: 1H NMR (400MHz, CDCl 3) δ 8.09 (s, 1H), 7.81 (d, J=8.2Hz, 2H), 7.72 (d, J=12.9Hz, 1H), 7.44 (d, J=8.2Hz; 2H), 7.11 (t, J=4.7Hz, 1H), 7.06 (d, J=7.8Hz, 1H), 4.05 (t, J=6.0Hz, 2H); 3.52-3.48 (m, 2H), 3.26-3.20 (m, 4H), 2.85 (t, J=5.5Hz, 2H), 2.59-2.54 (m, 4H); 2.50 (t, J=5.8Hz, 2H), 2.30 (s, 3H), 2.24 (s, 6H), 1.98-1.91 (m, 2H); LC-MSm/z:519 [M+H] +.
Compound F 17-hydroxy-corticosterone P-C7
Embodiment 56: compound F 17-hydroxy-corticosterone P-C8's is synthetic
Method is with embodiment 50, and different is to replace F-C3 with F-D3, and replaces 2-Pyrrolidine base ethamine with 2-piperidyl ethamine, obtains light yellow solid.
Productive rate 27%: 1H NMR (400MHz, CDCl 3) δ 8.07 (s, 1H), 7.77 (d, J=8.2Hz, 2H), 7.69 (d, J=12.9Hz, 1H), 7.42 (d, J=8.2Hz, 2H); 7.18 (t, J=4.6Hz, 1H), 7.02 (d, J=7.8Hz, 1H), 4.02 (t, J=6.0Hz, 2H), 3.49-3.43 (m, 2H); 3.24-3.17 (m, 4H), 2.83 (t, J=5.5Hz, 2H), 2.56-2.50 (m, 4H), 2.48 (t, J=6.0Hz, 2H); 2.42-2.31 (m, 4H), 2.28 (s, 3H), 1.95-1.88 (m, 2H), 1.55-1.48 (m, 4H), 1.42-1.34 (m, 2H); LC-MS m/z:559 [M+H] +.
Figure GSA00000140984200332
Compound F 17-hydroxy-corticosterone P-C8
Embodiment 57: compound F 17-hydroxy-corticosterone P-D1's is synthetic
Method is with embodiment 50, and different is to replace 2-Pyrrolidine base ethamine with 3-Pyrrolidine base propylamine, obtains light yellow solid.
Productive rate 39%: 1H NMR (400MHz, CDCl 3) δ 8.81 (t, J=4.3Hz, 1H), 7.72 (d, J=8.2Hz, 2H), 7.65-7.60 (m, 2H), 7.42 (d; J=8.3Hz, 2H), 7.00 (d, J=7.8Hz, 1H), 4.12 (t, J=7.1Hz, 2H); 3.53-3.47 (m, 2H), 3.25-3.18 (m, 4H), 3.11 (t, J=6.0Hz, 2H), 2.63 (t; J=6.0Hz, 2H), 2.56-2.48 (m, 8H), 2.29 (s, 3H), 1.78-1.70 (m, 6H); LC-MS m/z:545 [M+H] +.
Figure GSA00000140984200341
Compound F 17-hydroxy-corticosterone P-D1
Embodiment 58: compound F 17-hydroxy-corticosterone P-D2's is synthetic
Method is with embodiment 50, and different is to replace 2-Pyrrolidine base ethamine with the 3-diethyl amino propylamine, obtains light yellow solid.
Productive rate 40%: 1H NMR (400MHz, CDCl 3) δ 8.74 (t, J=4.4Hz, 1H), 7.73 (d, J=8.3Hz, 2H), 7.65-7.57 (m, 2H), 7.42 (d; J=8.3Hz, 2H), 6.98 (d, J=7.8Hz, 1H), 4.10 (t, J=7.1Hz, 2H), 3.54-3.44 (m; 2H), 3.19 (t, J=6.0Hz, 4H), 3.11 (t, J=6.0Hz, 2H), 2.59-2.45 (m; 10H), 2.27 (s, 3H), 1.74-1.64 (m, 2H), 0.96 (t, J=7.1Hz, 6H); LC-MS m/z:547 [M+H] +.
Figure GSA00000140984200342
Compound F 17-hydroxy-corticosterone P-D2
Embodiment 59: compound F 17-hydroxy-corticosterone P-D3's is synthetic
Method is with embodiment 50, and different is to replace 2-Pyrrolidine base ethamine with the 3-DIMAPA, obtains light yellow solid.
Productive rate 28%: 1H NMR (400MHz, CDCl 3) δ 8.44 (s, 1H), 7.67 (d, J=8.0Hz, 2H), 7.53-7.45 (m, 2H), 7.33 (d, J=8.0Hz; 2H), 6.91 (d, J=7.7Hz, 1H), 4.02 (t, J=6.0Hz, 2H), 3.47-3.38 (m; 2H), and 3.19-3.09 (m, 4H), 3.03-2.95 (m, 2H), 2.52-2.45 (m, 4H), 2.43 (t; J=6.2Hz, 2H), 2.24 (s, 3H), 2.23 (s, 6H), 1.74-1.66 (m, 2H); LC-MS m/z:519 [M+H] +.
Figure GSA00000140984200351
Compound F 17-hydroxy-corticosterone P-D3
Embodiment 60: compound F 17-hydroxy-corticosterone P-D4's is synthetic
Method is with embodiment 50, and different is to replace 2-Pyrrolidine base ethamine with 3-piperidyl propylamine, obtains light yellow solid.
Productive rate 31%: 1H NMR (400MHz, CDCl 3) δ 8.58 (s, 1H), 7.73 (d, J=8.0Hz, 2H), 7.58-7.52 (m, 2H), 7.37 (d, J=8.0Hz, 2H); 6.94 (d, J=7.7Hz, 1H), 4.06 (t, J=6.8Hz, 2H), 3.45-3.41 (m, 2H), 3.20-3.13 (m; 4H), and 3.08-3.00 (m, 2H), 2.52-2.46 (m, 4H), 2.43-2.39 (m, 2H), 2.38-2.27 (m, 4H); 2.25 (s, 3H), 1.69 (t, J=6.0Hz, 2H), 1.51-1.45 (m, 4H), 1.41-1.33 (m, 2H); LC-MS m/z:559 [M+H] +.
Figure GSA00000140984200352
Compound F 17-hydroxy-corticosterone P-D4
Embodiment 61: compound F 17-hydroxy-corticosterone P-D5's is synthetic
Method is with embodiment 50, and different is to replace F-C3 with F-D3, and replaces 2-Pyrrolidine base ethamine with 3-Pyrrolidine base propylamine, and with obtaining light yellow solid.
Productive rate 30%: 1H NMR (400MHz, CDCl 3) δ 8.88 (s, 1H), 8.07 (s, 1H), 7.74 (d, J=8.1Hz, 2H), 7.68 (d, J=12.9Hz; 1H), 7.40 (d, J=8.1Hz, 2H), 7.02 (d, J=7.8Hz, 1H), 4.02 (t, J=4.0Hz; 2H), and 3.52-3.47 (m, 2H), 3.23-3.16 (m, 4H), 2.86-2.81 (m, 2H), 2.63 (t, J=6.0Hz; 2H), 2.55-2.47 (m, 8H), 2.27 (s, 3H), 1.95-1.89 (m, 2H), 1.76-1.70 (m, 6H); LC-MS m/z:559 [M+H] +.
Figure GSA00000140984200361
Compound F 17-hydroxy-corticosterone P-D5
Embodiment 62: compound F 17-hydroxy-corticosterone P-D6's is synthetic
Method is with embodiment 50, and different is to replace F-C3 with F-D3, and replaces 2-Pyrrolidine base ethamine with the 3-diethyl amino propylamine, obtains light yellow solid.
Productive rate 25%: 1H NMR (400MHz, CDCl 3) δ 8.85 (s, 1H), 8.11 (s, 1H), 7.79 (d, J=8.1Hz, 2H), 7.74 (d, J=12.9Hz, 1H); 7.45 (d, J=8.1Hz, 2H), 7.07 (d, J=7.8Hz, 1H), 4.07 (t, J=4.0Hz, 2H); 3.56-3.51 (m, 2H), 3.27-3.21 (m, 4H), 2.88 (t, J=5.4Hz, 2H), 2.60-2.51 (m, 10H); 2.32 (s, 3H), 2.00-1.93 (m, 2H), 1.76-1.68 (m, 2H), 1.00 (t, J=7.1Hz, 6H); LC-MS m/z:561 [M+H] +.
Figure GSA00000140984200362
Compound F 17-hydroxy-corticosterone P-D6
Embodiment 63: compound F 17-hydroxy-corticosterone P-D7's is synthetic
Method is with embodiment 50, and different is to replace F-C3 with F-D3, and replaces 2-Pyrrolidine base ethamine with the 3-DIMAPA, obtains light yellow solid.
Productive rate 27%: 1H NMR (400MHz, CDCl 3) δ 8.55 (t, J=4.3Hz, 1H), 8.10 (s, 1H), 7.76 (d, J=8.2Hz, 2H), 7.72 (d, J=12.9Hz; 1H), 7.44 (d, J=8.2Hz, 2H), 7.05 (d, J=7.8Hz, 1H), 4.05 (t, J=6.0Hz, 2H); 3.54-3.48 (m, 2H), 3.26-3.20 (m, 4H), 2.87 (t, J=5.5Hz, 2H), 2.59-2.53 (m, 4H), 2.45 (t; J=5.9Hz, 2H), 2.30 (s, 3H), 2.25 (s, 6H), 1.98-1.91 (m, 2H), 1.76-1.69 (m, 2H); LC-MSm/z:533 [M+H] +.
Compound F 17-hydroxy-corticosterone P-D7
Embodiment 64: compound F 17-hydroxy-corticosterone P-D8's is synthetic
Method is with embodiment 50, and different is to replace F-C3 with F-D3, and replaces 2-Pyrrolidine base ethamine with 3-piperidyl propylamine, obtains light yellow solid.
Productive rate 27%: 1H NMR (400MHz, CDCl 3) δ 8.71 (t, J=4.4Hz, 1H), 8.13 (s, 1H), 7.86 (d, J=8.3Hz, 2H), 7.76 (d; J=12.9Hz, 1H), 7.47 (d, J=8.2Hz, 2H), 7.09 (d, J=7.9Hz, 1H), 4.09 (t; J=6.0Hz, 2H), 3.56-3.51 (m, 2H), 3.28-3.22 (m, 4H), 2.89 (t, J=5.5Hz, 2H); 2.60-2.56 (m, 4H), 2.54 (t, J=6.0Hz, 2H), 2.52-2.35 (m, 4H), 2.33 (s, 3H); 2.01-1.95 (m, 2H), 1.82-1.75 (m, 2H), 1.62-1.55 (m, 4H), 1.50-1.40 (m, 2H); LC-MS m/z:573 [M+H] +.
Figure GSA00000140984200372
Compound F 17-hydroxy-corticosterone P-D8
Embodiment 65: compound F 17-hydroxy-corticosterone-E2's is synthetic
Method is with embodiment 28, and different is to replace N methyl piperazine with piperidines, obtains white solid.
Productive rate 82%: 1H NMR (400MHz, CDCl3) δ 7.80 (d, J=13.0Hz, 1H), 7.06 (d, J=7.9Hz, 1H), 4.18 (t; J=6.0Hz, 2H), 3.20 (t, J=4.0Hz, 4H), 3.14 (t, J=7.9Hz; 2H), and 2.31-2.23 (m, 2H), 1.79-1.72 (m, 4H), 1.66-1.62 (m, 2H); LC-MS m/z:288 [M+H] +.
Figure GSA00000140984200381
Compound F 17-hydroxy-corticosterone-E2
Embodiment 66: compound F 17-hydroxy-corticosterone-E3's is synthetic
Method is with embodiment 29, and different is to replace F-I2 with F-E2, obtains yellow solid.
Productive rate 66%: 1H NMR (400MHz, CDCl 3) δ 8.31 (d, J=8.8Hz, 2H), 7.88-7.80 (m, 2H), 7.70 (d, J=8.8Hz, 2H); 7.18 (d, J=7.9Hz, 1H), 4.31 (t, J=6.0Hz, 2H), 3.36-3.30 (m, 2H); 3.24 (t, J=6.0Hz, 4H), 1.82-1.73 (m, 4H), 1.69-1.62 (m, 2H); LC-MS m/z:421 [M+H] +.
Figure GSA00000140984200382
Compound F 17-hydroxy-corticosterone-E3
Embodiment 67: compound F 17-hydroxy-corticosterone-E4's is synthetic
Method is with embodiment 30, and different is to replace F-I3 with F-E3, obtains yellow solid.
Productive rate 71%:1H NMR (400MHz, CDCl3) δ 7.81 (d, J=13.0Hz, 1H), 7.72 (s, 1H), 7.40 (d; J=8.5Hz, 1H), 7.17 (s, 1H), 6.72 (d, J=8.5Hz; 2H), 4.26 (t, J=6.0Hz, 1H), 3.95 (s, 1H); 3.28-3.18 (m, 3H), 1.80-1.73 (m, 2H), 1.67-1.61 (m, 1H); LC-MS m/z:391 [M+H] +.
Figure GSA00000140984200383
Compound F 17-hydroxy-corticosterone-E4
Embodiment 68: compound F 17-hydroxy-corticosterone P-E1's is synthetic
Method is with embodiment 35, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces F-I4 with F-E4, gets light yellow solid.
Productive rate 51%:1H NMR (400MHz, CDCl3) δ 11.50 (s, 1H), 7.79 (d, J=13.0Hz, 1H), 7.71 (t, J=2.4Hz, 1H), 7.57 (d; J=8.6Hz, 2H), 7.49 (d, J=8.7Hz, 2H), 7.13 (d, J=7.9Hz, 1H), 4.24 (t, J=8.0Hz; 2H), 3.28-3.23 (m, 2H), 3.20 (t, J=6.0Hz, 4H), 2.88 (t, J=6.0Hz, 2H), 2.71 (s; 4H), 2.57 (t, J=4.0Hz, 2H), 1.92 (s, 4H), 1.79-1.72 (m, 4H), 1.66-1.60 (m, 2H); LC-MS m/z:516 [M+H] +.
Compound F 17-hydroxy-corticosterone P-E1
Embodiment 69: compound F 17-hydroxy-corticosterone P-E2's is synthetic
Method is with embodiment 35, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces F-I4 with F-E4, and replaces Pyrrolidine with diethylamine, gets light yellow solid.
Productive rate 46%: 1H NMR (400MHz, CDCl 3) δ 11.48 (s, 1H), 7.79 (d, J=13.0Hz, 1H), 7.71 (s, 1H), 7.62 (d, J=8.6Hz, 2H); 7.49 (d, J=8.5Hz, 2H), 7.13 (d, J=7.9Hz, 1H), 4.24 (t, J=7.2Hz, 2H); 3.27-3.19 (m, 6H), 2.82 (t, J=4.0Hz, 2H), 2.71 (q, J=7.1Hz, 4H), 2.55 (t; J=6.0Hz, 2H), 1.78-1.73 (m, 4H), 1.66-1.60 (m, 2H), 1.16 (t, J=7.1Hz, 6H); LC-MS m/z:518 [M+H] +.
Compound F 17-hydroxy-corticosterone P-E2
Embodiment 70: compound F 17-hydroxy-corticosterone P-E3's is synthetic
Method is with embodiment 35, and different is to replace the 2-chloroacetyl chloride with the 3-chlorpromazine chloride, and replaces F-I4 with F-E4, and replaces Pyrrolidine with piperidines, gets light yellow solid.
Productive rate 47%: 1H NMR (400MHz, CDCl 3) δ 11.59 (s, 1H), 7.75 (d, J=13.0Hz, 1H), 7.68 (s, 1H), 7.60 (d; J=8.5Hz, 2H), 7.47 (d, J=8.5Hz, 2H), 7.11 (d, J=7.9Hz, 1H); 4.21 (t, J=7.2Hz, 2H), 3.24-3.16 (m, 6H), 2.68 (t, J=6.0Hz; 2H), and 2.64-2.47 (m, 6H), 1.77-1.68 (m, 8H), 1.64-1.53 (m, 4H); LC-MS m/z:530 [M+H] +.
Figure GSA00000140984200401
Compound F 17-hydroxy-corticosterone P-E3
Table 1 compound when 10 μ mol/L to the active restraining effect of Telomerase
Figure GSA00000140984200402
Embodiment 71: the said Quinzolone derivatives of this patent is to the restraining effect of Telomerase
Select the representative compound of part, adopt the TRAP method to carry out the cell-free system telomerase activity.From human breast cancer cell strain MCF-7, extract total protein (including Telomerase); A certain amount of total protein extracting solution and medicament mixed to be measured are added in the TRAP reaction mixture; Utilize fluorescence gel imager or fluorescence microplate reader to detect after the PCR reaction, the result is as shown in table 1.The result shows when the described compound of this patent is 10 μ mol/L in concentration, external Telomerase is had obvious restraining effect.Therefore to can be used for preparing with the Telomerase be the cancer therapy drug of target spot to novel quinazoline ketone derivatives of the present invention.
Embodiment 72: the said Quinzolone derivatives of this patent is to the restraining effect of growth of tumour cell
Select the representative compound of part,, adopt mtt assay to carry out the cell in vitro poison and measure with two kinds of tumor cell line NCI-H460 (human lung adenocarcinoma cell line), GLC-82 (human lung adenocarcinoma cell line).The logarithmic phase cell adds the novel quinazoline ketone derivatives of different concns, acts on after 48 hours, measures its absorbancy.Calculate the compound concentration that cell growth inhibiting reaches at 50% o'clock respectively, with IC 50Value representation, the result is as shown in table 2.The result shows that the said compound of this patent all has stronger restraining effect external to these two kinds of tumor cell lines.Therefore Quinzolone derivatives of the present invention can be used for preparing anticancer medicine.
Embodiment 73: the said Quinzolone derivatives acute toxicity test of this patent
Select the representative compound (like FP-b2) of part, carry out acute toxicity test.Get 18-22 gram mouse and divide six groups at random; Every group of 10 mouse; Handle with saline water, DMSO 2.5ml/kg, FP-b2500mg/kg, FP-b2200mg/kg, FP-b2100mg/kg, FP-b250mg/kg respectively; Observed 14 days, 45% death of the visible 500mg/kg group of result mouse, promptly FP-b2 is approximately 500mg/kg to the acute toxicity LD50 value of mouse.Therefore the acute toxicity of Quinzolone derivatives of the present invention is less, can be used for preparing cancer therapy drug.
Table 2 formula I compound is to the restraining effect (IC of tumor cell line growth 50/ μ M)
Figure GSA00000140984200421

Claims (2)

1. Quinzolone derivatives is characterized in that structural formula is:
Figure FSB00000819967400011
Figure FSB00000819967400021
Figure FSB00000819967400031
Figure FSB00000819967400041
Figure FSB00000819967400061
2. the purposes of Quinzolone derivatives as claimed in claim 1 in the preparation cancer therapy drug.
CN2010101863715A 2010-05-21 2010-05-21 Quinnazolidone derivative, preparation method thereof and purpose of serving as anticarcinogen Expired - Fee Related CN101857595B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010101863715A CN101857595B (en) 2010-05-21 2010-05-21 Quinnazolidone derivative, preparation method thereof and purpose of serving as anticarcinogen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010101863715A CN101857595B (en) 2010-05-21 2010-05-21 Quinnazolidone derivative, preparation method thereof and purpose of serving as anticarcinogen

Publications (2)

Publication Number Publication Date
CN101857595A CN101857595A (en) 2010-10-13
CN101857595B true CN101857595B (en) 2012-11-21

Family

ID=42943781

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010101863715A Expired - Fee Related CN101857595B (en) 2010-05-21 2010-05-21 Quinnazolidone derivative, preparation method thereof and purpose of serving as anticarcinogen

Country Status (1)

Country Link
CN (1) CN101857595B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102382064B (en) * 2011-09-15 2014-01-15 中山大学 Quinnazolidone derivative, preparation method for same and application thereof
CN106220631B (en) * 2016-07-26 2019-02-05 中山大学 A kind of 7 fluorine replace Isaindigotone derivative and preparation method thereof and are preparing the application in anticancer drug
CN107522700B (en) * 2017-08-03 2020-03-20 中山大学 Quinazolinone and α -unsaturated ketone conjugated derivative and preparation method and application thereof
CN109232576B (en) * 2018-10-22 2020-07-17 信阳师范学院 7-substituted desoxypeganone base and preparation method and application thereof
CN114249733B (en) * 2021-07-16 2023-05-12 兰州大学 Isaindigotone derivative and application thereof in preparation of antitumor drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1886384A (en) * 2003-11-25 2006-12-27 希龙公司 Quinazolinone compounds as anticancer agents
CN101250189A (en) * 2008-03-25 2008-08-27 中山大学 Bisfatty amido substituted quinazolone derivatives as well as preparation method and use thereof as anti-cancer drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1886384A (en) * 2003-11-25 2006-12-27 希龙公司 Quinazolinone compounds as anticancer agents
CN101250189A (en) * 2008-03-25 2008-08-27 中山大学 Bisfatty amido substituted quinazolone derivatives as well as preparation method and use thereof as anti-cancer drugs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A.Sh.Abdurazakov.et al.REACTION OF 2,3-TETRAMETHYLEN-3,4-DIHYDROQUINAZOL-4-ONE AND ITS DERIVATIVES WITH AROMATIC ALDEHYDES AND FURFUROL.《Chemistry of Natural Compounds》.2009,第45卷(第3期),第402-408页.
D.P.Jindal,et al..Synthesis and bronchodilatory activity of some nitrogen bridgehead compounds.《European Journal of Medicinal Chemistry》.2002,第37卷第419-425页.
REACTION OF 2,3-TETRAMETHYLEN-3,4-DIHYDROQUINAZOL-4-ONE AND ITS DERIVATIVES WITH AROMATIC ALDEHYDES AND FURFUROL;A.Sh.Abdurazakov.et al;《Chemistry of Natural Compounds》;20091231;第45卷(第3期);第402-408页 *
Synthesis and bronchodilatory activity of some nitrogen bridgehead compounds;D.P.Jindal,et al.;《European Journal of Medicinal Chemistry》;20021231;第37卷;第419-425页 *

Also Published As

Publication number Publication date
CN101857595A (en) 2010-10-13

Similar Documents

Publication Publication Date Title
CN101580477B (en) Dehydroabietylamine derivatives and application thereof in bactericidal and antineoplastic medicaments
EP3675839B1 (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof
CN101857595B (en) Quinnazolidone derivative, preparation method thereof and purpose of serving as anticarcinogen
CN102295635B (en) Antitumor medicament tetralin amide compounds and pharmaceutically acceptable salts thereof as well as preparation method and application of antitumor medicament tetralin amide compounds
CN103320118A (en) Schiff base cooper ion fluorescence probe and preparation method thereof
CN101633640A (en) Naphthalimide derivative
CN107417695B (en) Berberine derivatives, preparation method thereof, pharmaceutical composition and anti-tumor application thereof
CN101250189B (en) Bisfatty amido substituted quinazolone derivatives as well as preparation method and use thereof as anti-cancer drugs
CN105130927B (en) One class benzene connection azacyclo- chalcone derivative and its preparation method and application
CN101967135A (en) 4-aryl coumarin compound and preparation method and application thereof
CN101967127B (en) Quinazoline derivative and preparation method thereof and application of quinazoline derivative for preparing anticancer drugs
CN101638389A (en) Polyamine derivative containing naphthalimide structure, preparation method and application thereof
CN102382164A (en) Toad lactam compound as well as preparation method and application thereof
CN103204808A (en) Biquinoline derivative, preparation method thereof and application thereof in preparing anticancer medicament
CN102267983A (en) Sym-triazine derivative compounds containing sym-tetrazine rings and preparation method thereof
CN102382064B (en) Quinnazolidone derivative, preparation method for same and application thereof
CN106554362B (en) It is a kind of using 1- pyridines-B-carboline as copper chloride (II) chelate and its synthetic method of ligand and application
CN101985449B (en) Coumarin derivative, and preparation method and use thereof as anti-cancer medicament
CN103601730A (en) Crown ether ring-shaped quinazoline nitrogen mustard compound, and preparation method and application thereof in tumor treatment
CN104098524B (en) 1-meta-methoxy benzoyl-3-phenyl-Isosorbide-5-Nitrae-dihydro-1,2,4,5-tetrazine and Synthesis and applications
CN108148068B (en) Pyrazolo [1,5-a ] pyridine drug molecule with antitumor activity and preparation method and application thereof
CN107602518B (en) Coumarin-dithiocarbamate derivative and synthesis method thereof
CN102491972B (en) Carbazole derivative, preparation method thereof, and application of carbazole derivative serving as anticancer drug
CN109575020A (en) Beta-carboline derivatives and preparation method thereof and application in preparation of anti-tumor drugs
CN103193857A (en) Holarrhine alkaloid derivative and application of holarrhine alkaloid derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121121

Termination date: 20190521

CF01 Termination of patent right due to non-payment of annual fee